Amgen is set to report its Q3 results on November 3, with management warning of a significant increase in operating expenses, including a $100 million upfront payment related to R&D. While the stock has risen over 41% this year, analysts expect slower profit growth despite revenue growth of around 5.4%. Key factors include rising R&D costs for late-stage drug trials and pressure from biosimilar competition on legacy products. The upcoming report will reveal if Amgen's investments in its pipeline can sustain revenue growth and maintain profitability margins.
Amgen shares on Pluang are trading at USD 463.50, up 2.58% as of October 29, 2026, 16:21 WIB, reflecting strong investor interest despite concerns about rising expenses. The stock's market cap stands at $242.18 billion, and it offers a dividend yield of 2.25%. With 82% of Pluang users buying and a typical hold time of 73 days, Amgen remains a favored health sector stock amid the upcoming Q3 earnings report.
Amgen announced it will report its third quarter 2026 financial results on November 3, 2026, after U.S. markets close. The earnings release will be followed by a conference call with CEO Robert A. Bradway and senior management at 4:30 p.m. ET for inv...
Amgen announced positive Phase 3 OASIZ-301 trial results for dazodalibep, a CD40L antagonist, showing significant and meaningful reductions in systemic disease activity and patient-reported dryness in adults with moderate-to-severe Sjögren's disease....
Amgen Inc. will announce its Q3 earnings on November 3, following a strong Q2 where non-GAAP EPS rose 25.8% to $6.29, driven by biosimilars and key drugs like Blincyto and Repatha. Recently, Amgen reported encouraging results from a lung cancer drug ...
Amgen has appointed David W. Gibbs, former CEO of Yum! Brands, to its Board of Directors. Gibbs brings extensive leadership experience from the consumer brand sector and will serve on Amgen's Audit and Compensation Committees. His background in digit...
